Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joint Panel Recommends Tysabri For Crohn’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

The highly restricted Tysabri risk management program tipped the risk-benefit scale in Biogen Idec/Elan’s favor.

You may also be interested in...



Tysabri Clears FDA For Moderate To Severe Crohn’s Disease

Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.

Tysabri Clears FDA For Moderate To Severe Crohn’s Disease

Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.

UCB’s Cimzia Rejected For Crohn’s By EMEA Committee

Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel